Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Dr reddy org - The Real Truth

Dr Reddy's launches oral semaglutide biosimilar Obeda in India

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the ease of a once-daily oral dosage, available in various strengths to effectively enhance glycaemic control. Dr.

The Economic Times

Stocks in news: Vodafone Idea, Indian Oil, Tata Steel, Dr Reddy's, PFC

Markets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict implications for oil and inflation. Vodafone Idea reported a Rs 51,970 crore net profit due to an accounting gain, while Tata Steel and Hindustan Copper saw significant profit growth in Q4FY26.

The Economic Times

Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada is the first G7 nation to approve this medication. The launch follows a recent introduction in India. Dr Reddy's aims to expand access…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

MarketBeat

Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in

Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.

The Economic Times

Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon Technologies

Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150. Several companies like Airtel, Tata Motors, and Dr Reddy's are in focus due to earnings reports and other news developments.

The Economic Times

Stocks in news: Groww, Dr Reddy's, Waaree Energies, Lenskart, SBI

Markets experienced a sharp risk-off session on Monday, with indices declining amid broad selling. Investors are advised to avoid aggressive index bets and await clearer directional signals. Pharma and healthcare stocks remain preferred, while dips in energy and metal sectors offer accumulation opportunities.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Dr. Reddy's Strategic Vision Reiterated Following Strong Q1FY25 Results

Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.

International Business Times

People

Reddy

24 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.